Spots Global Cancer Trial Database for myeloproliferative disorders
Every month we try and update this database with for myeloproliferative disorders cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | NCT06315309 | GVHD,Acute Acute Leukemia Myelodysplastic... Myeloproliferat... | ATG Combined wi... | 18 Years - 60 Years | University of Alabama at Birmingham | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms | NCT02580903 | Myeloproliferat... Pulmonary Hyper... | Radiology | 18 Years - | Odense University Hospital | |
| An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes | NCT01381809 | Myelodysplastic... | Group 2: Placeb... Group 1: Epoeti... | 18 Years - | Janssen-Cilag International NV | |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | NCT01998828 | Polycythemia Ve... Essential Throm... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms | NCT02580903 | Myeloproliferat... Pulmonary Hyper... | Radiology | 18 Years - | Odense University Hospital | |
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study | NCT04631211 | Thrombocytopeni... Hematologic Mal... Bone Marrow Apl... Myeloproliferat... Myelodysplastic... Platelet Refrac... | Thrombosomes Liquid Stored P... | 18 Years - | Cellphire Therapeutics, Inc. | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| Study of SB939 in Subjects With Myelofibrosis | NCT01200498 | Myeloproliferat... | SB939 | 18 Years - | M.D. Anderson Cancer Center | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | NCT00361140 | Myelodysplastic... Myeloproliferat... Leukemia, Lymph... Myeloma Lymphoma | Busulfan Fludarabine | 16 Years - 65 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | NCT02292446 | Polycythemia Ve... | Ruxolitinib | 18 Years - | Novartis | |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | NCT00967343 | Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat... | Donor lymphocyt... | 18 Years - 65 Years | Kiadis Pharma | |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies | NCT00186342 | Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia | ablative alloge... | 51 Years - 60 Years | Stanford University | |
| I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients | NCT05842603 | Myeloproliferat... Leukemia | Cardiac Lifesty... | 18 Years - | Massachusetts General Hospital | |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | NCT06303193 | Myelodysplastic... | pacritinib | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | NCT00967343 | Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat... | Donor lymphocyt... | 18 Years - 65 Years | Kiadis Pharma | |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples | NCT05001386 | Myeloproliferat... Lymphoprolifera... | Blood collectio... | 18 Years - | Hospices Civils de Lyon | |
| Study of SB939 in Subjects With Myelofibrosis | NCT01200498 | Myeloproliferat... | SB939 | 18 Years - | M.D. Anderson Cancer Center | |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies | NCT00186342 | Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia | ablative alloge... | 51 Years - 60 Years | Stanford University | |
| Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | NCT02467270 | Myeloid Leukemi... | Ponatinib | 18 Years - | Takeda | |
| Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) | NCT02252159 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD | NCT00185796 | Myeloproliferat... Blood Cancer Myelodysplastic... | Total Lymphoid ... Anti-Thymocyte ... | 49 Years - 75 Years | Stanford University | |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving | NCT01684150 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... | EPZ-5676 | 18 Years - 90 Years | Ipsen | |
| Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant | NCT06265584 | Acute Leukemia Myelodysplastic... Myeloproliferat... | ATG dosing plat... | 18 Years - 75 Years | University of Alabama at Birmingham | |
| MSC and HSC Coinfusion in Mismatched Minitransplants | NCT01045382 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myeloproliferat... Myelodysplastic... Multiple Myelom... Leukemia, Lymph... Hodgkin's Disea... Lymphoma, Non-H... | Mesenchymal ste... Isotonic soluti... | - 75 Years | University of Liege | |
| Study of DISC-0974 in Participants With Myelofibrosis and Anemia | NCT05320198 | Myelofibrosis; ... Anemia Myelofibrosis Myelofibrosis D... Primary Myelofi... Post-essential ... | DISC-0974 | 18 Years - | Disc Medicine, Inc | |
| A Safety Study of XL019 in Adults With Myelofibrosis | NCT00522574 | Myeloproliferat... Myelofibrosis Polycythemia Ve... Thrombocythemia... | XL019 | 18 Years - | Exelixis | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | NCT00745550 | Myelofibrosis Myeloproliferat... Polycythemia Ve... Essential Throm... | SB1518 | 18 Years - | S*BIO | |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | NCT04173494 | Primary Myelofi... Post-polycythem... Post-essential ... | Momelotinib Placebo to matc... Danazol Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | NCT01392989 | Neural Tube Def... Anemia Leukemia, Myelo... Bone Marrow Tra... Myelodysplastic... Myeloproliferat... | CIK cells Cyclosporine Mycophenolate M... Thymoglobulin Total Lymphoid ... | 50 Years - | Stanford University | |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | NCT02038036 | Polycythemia Ve... | Best Available ... Ruxolitinib | 18 Years - | Novartis | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 | NCT02320656 | Acute Leukemia Myelodysplastic... Myeloproliferat... | Blood sampling Bone marrow asp... Skin biopsy Buccal swab | 18 Years - | Institut Paoli-Calmettes | |
| Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | NCT00074490 | Lymphoma Leukemia Myeloproliferat... Multiple Myleom... Myelodysplastic... | Rituximab Fludarabine Etoposide Doxorubicin Vincristine Cyclophosphamid... Peripheral bloo... T cell donor ly... Prednisone Allogeneic hema... Filgrastim T-Rapa cell Don... | 11 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | NCT00295880 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | umbilical cord ... | 12 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | NCT02038036 | Polycythemia Ve... | Best Available ... Ruxolitinib | 18 Years - | Novartis | |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | NCT06150157 | Myeloproliferat... Essential Throm... Neoplasms Myelofibrosis | JNJ-88549968 | 18 Years - | Janssen Research & Development, LLC | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | NCT05823571 | Leukemia, Acute Myelodysplastic... Myelomonocytic ... T-cell Prolymph... CML Myeloproliferat... Multiple Myelom... Plasma Cell Leu... | Itacitinib | 60 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | NCT00943293 | Preleukemia Myeloproliferat... Lymphoma Myeloma Graft Versus Ho... | Fludarabine Melphalan Campath | 18 Years - | University of Chicago | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia | NCT02627677 | Chronic Phase C... | Ponatinib 30 mg... Ponatinib 15 mg... Nilotinib 400 m... | 18 Years - | Takeda | |
| TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD | NCT00185796 | Myeloproliferat... Blood Cancer Myelodysplastic... | Total Lymphoid ... Anti-Thymocyte ... | 49 Years - 75 Years | Stanford University | |
| Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | NCT00715247 | Polycythemia Ve... Essential Throm... Myelofibrosis | - | University of Utah | ||
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. | NCT02218047 | Polycythemia Ve... | Pegylated-Proli... Best available ... | 18 Years - | AOP Orphan Pharmaceuticals AG | |
| Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | NCT00305682 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | anti-thymocyte ... cyclophosphamid... Fludarabine mycophenolate m... umbilical cord ... total body irra... Sirolimus | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | NCT04709458 | Myelofibrosis Acute Myelogeno... | TBX-2400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders | NCT00511537 | CML ALL AML Myelodysplasia Lymphoma Myeloproliferat... | 16 Years - 54 Years | University of California, San Francisco | ||
| Investigation of the Cylex® ImmuKnow® Assay | NCT00569842 | Leukemia Non-Hodgkin's L... Chronic Lymphoc... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... Aplastic Anemia Chronic Myeloge... | 18 Years - | Indiana University | ||
| I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients | NCT05842603 | Myeloproliferat... Leukemia | Cardiac Lifesty... | 18 Years - | Massachusetts General Hospital | |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples | NCT05001386 | Myeloproliferat... Lymphoprolifera... | Blood collectio... | 18 Years - | Hospices Civils de Lyon | |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders | NCT00858572 | AML CML MDS Myeloproliferat... | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. | |
| Pathogenesis of Hematologic Malignancies | NCT01728402 | Acute Leukemia Lymphoprolifera... Myeloproliferat... Myelodysplastic... | blood draw, bon... | 1 Year - | OHSU Knight Cancer Institute | |
| T-Reg Cell Kinetics, Stem Cell Transplant, REGALE | NCT00578539 | Leukemia Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... | ARA C Cyclophosphamid... MESNA Total Body Irra... Campath-1h Stem Cell Infus... | - | Baylor College of Medicine | |
| Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador | NCT05825326 | Myeloproliferat... Myeloproliferat... Myeloproliferat... Myeloproliferat... Myeloproliferat... | 18 Years - | Sociedad de Lucha Contra el Cáncer del Ecuador | ||
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving | NCT01684150 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... | EPZ-5676 | 18 Years - 90 Years | Ipsen | |
| Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases | NCT00056966 | Hematologic Mal... | ANTI-CD45 CAMPATH-1H FK506 Fludarabine Total Body Irra... Stem cell infus... | - | Baylor College of Medicine | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| T-Reg Cell Kinetics, Stem Cell Transplant, REGALE | NCT00578539 | Leukemia Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... | ARA C Cyclophosphamid... MESNA Total Body Irra... Campath-1h Stem Cell Infus... | - | Baylor College of Medicine | |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | NCT00361140 | Myelodysplastic... Myeloproliferat... Leukemia, Lymph... Myeloma Lymphoma | Busulfan Fludarabine | 16 Years - 65 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador | NCT05825326 | Myeloproliferat... Myeloproliferat... Myeloproliferat... Myeloproliferat... Myeloproliferat... | 18 Years - | Sociedad de Lucha Contra el Cáncer del Ecuador | ||
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | NCT05088356 | Allogeneic Hema... Advanced Hemato... Acute Leukemia Chronic Myeloge... Myelodysplastic... Myeloproliferat... | Purified regula... Fludarabine Melphalan CliniMACS CD34 ... Tacrolimus Cyclophosphamid... Plerixafor Filgrastim gran... Thiotepa Mycophenolate M... Ruxolitinib | 18 Years - 75 Years | Stanford University | |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | NCT06150157 | Myeloproliferat... Essential Throm... Neoplasms Myelofibrosis | JNJ-88549968 | 18 Years - | Janssen Research & Development, LLC | |
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | NCT05423691 | Myelofibrosis | CK0804 | 18 Years - | Cellenkos, Inc. | |
| Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders | NCT00186576 | Myelodysplastic... Myeloproliferat... Blood and Marro... Myelodysplastic... Myeloproliferat... | nonmyeloablativ... | 18 Years - 75 Years | Stanford University | |
| T-Reg Cell Kinetics, Stem Cell Transplant, REGALE | NCT00578539 | Leukemia Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... | ARA C Cyclophosphamid... MESNA Total Body Irra... Campath-1h Stem Cell Infus... | - | Baylor College of Medicine | |
| A Study in Myeloproliferative Disorders | NCT01134120 | Myeloproliferat... Thrombocythemia... Polycythemia Ve... Primary Myelofi... | LY2784544 | 18 Years - | Eli Lilly and Company | |
| Investigation of the Cylex® ImmuKnow® Assay | NCT00569842 | Leukemia Non-Hodgkin's L... Chronic Lymphoc... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... Aplastic Anemia Chronic Myeloge... | 18 Years - | Indiana University | ||
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | NCT04709458 | Myelofibrosis Acute Myelogeno... | TBX-2400 | 18 Years - | Taiga Biotechnologies, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
